Overview
Atorvia is a pre-clinical stage biotech company on a mission to end kidney failure. Our research into what causes organ dysfunction uncovered a new biological target: a known protein with a previously unknown function in how cells become programmed to die. We are engineering novel peptide-based drugs that specifically target it in the kidney cells with pre-clinical data suggesting this approach could become a safe and effective solution in kidney failure. We plan to first tackle Acute Kidney Injury (AKI) which affects millions of patients each year who are undergoing transplant, heart surgery and liver surgery. It can have life threatening consequences, currently can’t be prevented and there is no treatment available for it today.
Our research into better understanding functional proteomics in kidney failure has also revealed novel protein biomarkers that
could change how patients are diagnosed, and allow detection of early stage kidney failure before traditional, surrogate endpoints are currently able to.
A Boston University spinout, we are headquartered in Ottawa with wet lab space in Toronto and a team that operates between Canada and Massachusetts.